Muutke küpsiste eelistusi

Oncolytic Viruses 2020 ed. [Pehme köide]

  • Formaat: Paperback / softback, 329 pages, kõrgus x laius: 254x178 mm, kaal: 655 g, 48 Illustrations, color; 16 Illustrations, black and white; XI, 329 p. 64 illus., 48 illus. in color., 1 Paperback / softback
  • Sari: Methods in Molecular Biology 2058
  • Ilmumisaeg: 05-Sep-2020
  • Kirjastus: Humana Press Inc.
  • ISBN-10: 1493997963
  • ISBN-13: 9781493997961
Teised raamatud teemal:
  • Pehme köide
  • Hind: 113,55 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 133,59 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Paperback / softback, 329 pages, kõrgus x laius: 254x178 mm, kaal: 655 g, 48 Illustrations, color; 16 Illustrations, black and white; XI, 329 p. 64 illus., 48 illus. in color., 1 Paperback / softback
  • Sari: Methods in Molecular Biology 2058
  • Ilmumisaeg: 05-Sep-2020
  • Kirjastus: Humana Press Inc.
  • ISBN-10: 1493997963
  • ISBN-13: 9781493997961
Teised raamatud teemal:

This book aims to provide a guide for virologists, translational researchers, and clinicians in the field of cancer research by providing reference protocols and methodologies from vector development through clinical translation.   Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

 Authoritative and cutting-edge, Oncolytic Viruses: Methods and Protocols aims to ensure successful results in the further study of this vital field.

Introduction to Oncolytic Virotherapy.- Methods for Modification of
Therapeutic Viruses.- Tumor Targeting of Oncolytic Adenoviruses using
Bispecific Adapter Proteins.- Development of Entry-targeted Oncolytic Measles
Viruses.- Insert Stability and In Vivo Testing of MicroRNA-Detargeted
Oncolytic Picornaviruses.- Ex vivo Virotherapy with Myxoma Virus to Treat
Cancer.- Immunomodulation in Oncolytic Measles Virotherapy.- A Functional
Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic
Tumor Cell Death.- Design and Production of Newcastle Disease Virus for
Intratumoral Immunomodulation.- Analysis of Immunological Treatment Effects
of Virotherapy in Tumor Tissue.- Immunohistochemistry for Tumor-infiltrating
Immune Cells after Oncolytic Virotherapy.- Detection of Tumor
Antigen-specific T-cell Responses after Oncolytic Vaccination.- Evaluation of
Oncolytic Virus Induced Therapeutic Tumor Vaccination Effects in Murine Tumor
Models.- Delivery of Oncolytic Reovirus by Cell Carriers.- In Vivo Bioimaging
for Monitoring Intratumoral Virus Activity.- Oncolytic Immunotherapy for
Bladder Cancer Using Coxsackie A21 virus: Using a Bladder Tumour
Precision-cut Slice Model System to Assess Viral Efficacy.- Use of Liquid
Patient Ascites Fluids as a Pre-clinical Model for Oncolytic Virus Activity.-
Generating Primary Models of Human Cancer to Aid in the Development of
Clinically-relevant Oncolytic Viruses.- Considerations for Clinical
Translation of MG1 Maraba Virus.- Fluorescence in Situ Hybridization (FISH)
Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-treated Human
Brain Tumors.- Mathematical Modeling of Oncolytic Virotherapy.